Earnings Overview#
Lifecore Biomedical recently released its earnings report for the first quarter of 2026, showing a slight miss on both earnings per share (EPS) and revenue compared to market expectations. The company reported an EPS of -$0.16, which was slightly worse than the forecast of -$0.1575. Additionally, revenue came in at $35.15 million, falling short of the anticipated $37.05 million. Following this news, Lifecore's stock dropped by 9.88% in premarket trading, signaling investor concern over the company's performance.
Key Financial Metrics#
In Q1 2026, Lifecore Biomedical faced significant challenges, with revenues declining by 34% compared to the same quarter last year. This downturn was attributed to previously disclosed issues affecting the company. Despite efforts to cut costs, Lifecore reported a net loss of $15 million, which is slightly higher than the loss of $14.8 million reported in the previous year. Here are some key financial highlights: - Revenue: $35.15 million (down 34% year-over-year) - Earnings per share: -$0.16 (compared to -$0.42 in Q1 2025) - Gross profit: $4.5 million (down 55% from the previous year) - Operating expenses: $7.9 million (down 21% from Q1 2025) - Net loss: $15 million (compared to $14.8 million in Q1 2025)
Market Reaction#
The immediate market response to Lifecore's earnings report was negative, with the stock price falling to $4.65 in premarket trading. This decline reflects investor disappointment regarding the company's inability to meet earnings and revenue forecasts. The stock has seen a significant drop of 37% year-to-date and 22% over the past six months, contrasting sharply with its 52-week high of $8.98.
Future Outlook#
Despite the disappointing Q1 results, Lifecore's management has maintained its full-year guidance, projecting total revenues between $120 million and $125 million, along with an adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $20.5 million to $25 million. The company expects to generate approximately 45% of its revenue in the first half of 2026 and 55% in the latter half, indicating a potential recovery as the year progresses.